Abstract
During the last two decades, a rapidly increasing number of therapeutic antibodies have been generated and used in a variety of diseases. The rationale of passive immunotherapy is that, due to their unique specificity, antibodies can selectively target and act on molecules associated with pathological processes. However, how therapeutic antibodies actually act on target molecules and cells under specific conditions is poorly known. As a consequence, whether the efficacy of available antibodies could be increased and whether new antibodies could be tailored for specific purposes have not been thoroughly investigated. We discuss in this review how therapeutic antibodies interact with Fc receptors, what are the cellular responses induced by these interactions and how a better knowledge of these interactions and biological responses could improve antibody-based passive immunotherapy.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
